Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors.
about
Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretionMembrane transporters in drug developmentInvestigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.Identification of hepatic phospholipidosis inducers in sandwich-cultured rat hepatocytes, a physiologically relevant model, reveals altered basolateral uptake and biliary excretion of anionic probe substratesRole of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity.Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.Influence of seeding density and extracellular matrix on bile Acid transport and mrp4 expression in sandwich-cultured mouse hepatocytes.Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Inhibition of P-Glycoprotein and Multidrug Resistance-Associated Protein 2 Regulates the Hepatobiliary Excretion and Plasma Exposure of Thienorphine and Its Glucuronide Conjugate.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporineThe evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Primary hepatocyte cultures as prominent in vitro tools to study hepatic drug transporters.In vitro methods to support transporter evaluation in drug discovery and development.Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools.Transporter effects on cell permeability in drug delivery.A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies.Transport characteristics and transporter-based drug-drug interactions of TM-25659, a novel TAZ modulator.Predicting when biliary excretion of parent drug is a major route of elimination in humans.Evaluation of transporter-mediated hepatic uptake in a non-radioactive high-throughput assay: a study of kinetics, species difference and plasma protein effect.Bile canaliculi formation and biliary transport in 3D sandwich-cultured hepatocytes in dependence of the extracellular matrix composition.Prediction of hepatic plasma clearance in vivo from gel-entrapped rat and human hepatocytes.Enhanced bile canaliculi formation enabling direct recovery of biliary metabolites of hepatocytes in 3D collagen gel microcavities.Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes: A Proteomics-Informed Bottom-Up Approach.ADME
P2860
Q28570070-91B8BCF6-DE92-486C-B426-E70937D6E06FQ29616802-43752B25-F527-4767-919E-E65535827197Q33581531-EE8CFDBA-21E1-46B3-9720-362FD984CC9FQ33686976-2C2DB340-AD66-4AF2-B7EE-FBBBE2D8FD1DQ34125053-05C3E065-B6BC-446C-91D2-C54C91032998Q34330504-28EB4928-11DB-453F-9C37-7A49F30943BCQ34990717-122B8E4E-32B2-4F49-9F84-27579E0D3A2CQ35607383-41D39CDB-8F90-4941-8FD8-7F75C2332BFDQ36910606-A2E3C31F-9D42-4A5C-B349-68097A8E0EC1Q37159255-9F8191D2-C43C-426B-8963-4CD713E57BBDQ37394474-343E8AF7-89CD-4049-93CE-73344C1885E8Q37470663-479685C9-979F-42CC-93CA-0A4312DEA681Q37955160-2BA7002A-2191-48EF-A27C-AE0C5D2619F3Q38077993-45163570-F7D4-43FC-8A40-21439ECFF68FQ38099194-2C093142-027E-4696-88EA-8641D3ECE9B8Q38192698-22EB1965-2C97-4388-B3D5-7CC433862766Q38905979-138279FD-01E4-49B2-9E09-91FFEF683B6AQ39018278-60ADC8D6-D167-43FB-811C-0FDE2BD63177Q42450098-3B075B3D-C51B-4FA8-9B11-43305CC0F386Q42846727-62EBB9D0-5D5E-4B4F-94DD-8E7DDF1A3EC6Q47212461-288196AD-C73B-4793-A2C1-09E1633F18DEQ48192584-1B3B8F2A-6FD5-40A2-B3A4-21266A17467AQ51250114-FFA50E00-94ED-4BAE-B780-A892A82C2D49Q51541069-1AA10296-745F-4DFF-99E5-630E288E6FD3Q53188214-B6C6E16A-1426-4AF6-BA23-A82C2BAF9903Q57684720-12F66915-472C-48E4-B507-899C29DF6353
P2860
Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of sandwich-cultured human ...... HMG-CoA reductase inhibitors.
@en
Use of sandwich-cultured human ...... HMG-CoA reductase inhibitors.
@nl
type
label
Use of sandwich-cultured human ...... HMG-CoA reductase inhibitors.
@en
Use of sandwich-cultured human ...... HMG-CoA reductase inhibitors.
@nl
prefLabel
Use of sandwich-cultured human ...... HMG-CoA reductase inhibitors.
@en
Use of sandwich-cultured human ...... HMG-CoA reductase inhibitors.
@nl
P2860
P356
P1476
Use of sandwich-cultured human ...... d HMG-CoA reductase inhibitors
@en
P2093
Arlene S Bridges
P2860
P304
P356
10.1124/DMD.108.023465
P50
P577
2008-12-15T00:00:00Z